Brief: Early Results Of Betterlife Preclinical Study Show AP-003 (RHIFN⍺2B) Provides Up To 97% Protection In Human Cells Against The Delta Variant Of SARS-COV-2
12/10/2021 14:17
Oct 12 (Reuters) - BetterLife Pharma Inc BETR.CD :
* EARLY RESULTS OF BETTERLIFE PRECLINICAL STUDY SHOW AP-003
(RHIFN⍺2B) PROVIDES UP TO 97% PROTECTION IN HUMAN CELLS AGAINST
THE DELTA VARIANT OF SARS-COV-2
Source text for Eikon: ID:nGNX2CtcTY
Further company coverage: BETR.CD
Recent news on BetterLife Pharma
See all newsBrief: Betterlife Pharma Provides Scientific Update On Neuroplastogenic Activity Of BETR-001
Brief: Betterlife Pharma Advanced In IND-enabling Studies For BETR-001
Brief: BetterLife Announces Closing Of $1.168 Million Convertible Debentures To Further Advance IND-Enabling Studies Of Its Non-Hallucinogenic LSD-Based Drug Candidate BETR-001
Brief: Omineca Announces $2 Mln Brokered Financing Of Flow-Through Units
Brief: Betterlife Announces Pricing Of Proposed Offering Of Units